Form 4: Zomedica General Counsel Granted 500,000 Stock Options

Zomedica Corp.'s General Counsel, Karen DeHaan-Fullerton, was granted 500,000 options to purchase common stock at an exercise price of $0.05 per share, vesting over four years.

Summary

• Karen DeHaan-Fullerton, General Counsel of Zomedica Corp. (ZOMDF), was granted 500,000 options to purchase common stock.
• The options have an exercise price of $0.05 per share.
• The transaction date for the grant was June 12, 2025.
• The options expire on June 11, 2035.
• Vesting schedule: one quarter (1/4) of the options vest on the first anniversary of the grant date (June 12, 2026), and 1/48 vest monthly thereafter until fully vested on June 11, 2029.
• Following this transaction, Karen DeHaan-Fullerton beneficially owns 500,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign of management alignment and retention, though it's a routine compensation event rather than a major strategic announcement. The low exercise price offers potential upside.

Positives

• The grant of 500,000 stock options to General Counsel Karen DeHaan-Fullerton aligns her interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $0.05 per share is relatively low, offering significant potential upside if Zomedica's stock price increases.

Negatives

• The value of the options is contingent on the future performance of Zomedica's stock price, meaning they could become worthless if the stock price does not exceed the exercise price.

Risks

• The value of the granted stock options is subject to market fluctuations and the future performance of Zomedica Corp.'s common stock.
• If the company's stock price does not rise above the $0.05 exercise price, the options may not be exercised and could expire worthless.

Future Outlook

The options are subject to a vesting schedule, with 25% vesting on the first anniversary of the grant date (June 12, 2026) and the remaining 75% vesting monthly over the subsequent three years until fully vested by June 11, 2029. The options have a long-term expiration date of June 11, 2035, indicating a long-term incentive for the General Counsel.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation in the form of stock options. Such grants are common practice across various industries, including the animal health and veterinary diagnostics sector where Zomedica operates, to align executive incentives with shareholder value creation.

Comparison to Industry Standards

• This is a standard executive compensation grant. Without specific details on Zomedica's compensation philosophy or comparable grants at similar-sized companies in the animal health or veterinary diagnostics industry, a detailed comparison is not feasible from this document alone. However, stock option grants are a widely accepted form of long-term incentive compensation for executives across industries.

Related Party Transactions

• The grant of stock options to an officer of the company (Karen DeHaan-Fullerton, General Counsel) is a transaction between the company and a related party. This is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The grant aligns the General Counsel's financial interests with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: This grant is specific to a senior executive and does not directly impact the broader employee base, though it reflects the company's compensation practices for key personnel.

Next Steps

• The options will vest according to the specified schedule, with the first tranche vesting on June 12, 2026.
• The General Counsel may choose to exercise these options at any point after they vest and before their expiration date of June 11, 2035, subject to company policy and blackout periods.

Key Dates

Keywords

Zomedica Corp., ZOMDF, SEC Form 4, Stock Options, Executive Compensation, Derivative Securities, Insider Transaction, Karen DeHaan-Fullerton, General Counsel